‘Air to water' innovative tech comes to Texas amid water crisis
'There are 39 million billion gallons of water in the atmosphere around us,' said Brian Sheng, co-founder of water technology company Aquaria. 'Our machine is actually sucking in air first, and then we are lowering the atmospheric air into its dew point and then capturing that water.'
Brian is referring to the Hydropack system. About the size of a Coke machine, the large grey box pulls in air and uses it to create water. The machine does this by simulating the same processes that occur when dew forms on grass in the morning.
'Our family is from an area in China called 'the land of 1,000 springs,' right? It's actually very much like Texas,' said Brian's brother and fellow co-founder Eric Sheng. 'They're the province that makes all the raw steel. They're the province that makes a lot of military equipment, and all the water is polluted.'
Longhorn rancher, camp director worried proposed rock crusher could pollute water supply
Growing up, the brothers had water on the brain. They developed the Hydropack technology to address these concerns.
Now they're bringing the technology to Texas. Currently, seven of their products are located in the state. Two are in the Austin area, including a model in Manor.
The machine pulls in air, turns it into water and then deposits it in a tank for consumption. During this process, it passes through six filters in order to cleanse the water.
The smallest unit, called Hydropixel, can be placed indoors and generates 24 gallons of water per day. The largest unit, the Hydropack X, generates 246 gallons per day. All require power to work. Prices on the home units start at $10,000.
There are some downsides. For one, the machine works best in humid air. While it can create water in arid climates, it functions better near the coast.
Also, it doesn't work below a certain temperature. The closer to freezing, the less water in the air. However, when the air is hot it can pull in more water.
'In the future, we really envision ourselves to be supplying water for entire cities, for entire communities,' Eric said. The company plans to sell its first industrial-sized machines in the next two months.
The company currently has devices in several states and eight countries.
Similar technology has been developed at the University of Texas. There, Professor Guihua Yu has spent the last few years working on a hydrogel polymer.
That substance can absorb water directly from the air, which can then be squeezed out and drank.
University of Texas microgrid upgrade incoming; could prevent outages during extreme weather
'This actually is very easily accessible and extremely scalable and extremely also low cost material to start with,' Yu told KXAN in February 2024.
Hydrogel doesn't require power to use but is much smaller than the Hydropack.
Improving water stability in Texas is one of Gov. Greg Abbott's top goals of this current legislative session. Of those top priorities includes expanding the Texas Water Fund.
That fund, established as part of the 88th legislative session, provides a resource for communities looking to improve their water infrastructure. While an initial investment was provided for the fund, state lawmakers like Sen. Charles Perry are looking to reinforce that.
This session, Perry announced he aims to add a constitutional amendment to the state that would see the fund grow by a billion dollars per year for fifty years.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 hours ago
- Yahoo
Record breaking black hole discovered by UT Austin astronomers
AUSTIN (KXAN) — The most distant black hole ever confirmed has now been discovered. A team led by astronomers from the University of Texas at Austin announced the discovery of the black hole in the CAPERS-LRD-z9 galaxy earlier this month. The black hole is 300 million times more massive than our sun. In fact, it has more mass than half of the stars in its own galaxy combined. Discovered using the James Webb Space Telescope, the black hole formed 500 million years after the Big Bang. This makes it 13.3 billion years old. The team, led by UT Austin's Cosmic Frontier Center, published its work on Aug. 6 in Astrophysical Journal Letters. To discover black holes, astronomers look for a peculiar light signature that signals fast moving gas. Gas that moves towards us is compressed into blue wavelengths, while gas moving away from us appears red through spectroscopy. In a press release from UT Austin, the paper's lead author, Anthony Taylor, said, 'There aren't many other things that create this signature (besides a black hole).' The galaxy where the black hole was discovered is called a 'Little Red Dot' galaxy. These galaxies formed in the first 1.5 billion years of the universe. The first discovery of these galaxies was made by the James Webb Space Telescope, which launched in 2021. The discovery of this black hole gives us a better understanding of the early universe. In that same press release, Steven Finkelstein, a co-author of the paper, said, 'This adds to growing evidence that early black holes grew much faster than we thought possible.' The team hopes the next steps for its research are to use James Webb to get more data on the CAPERS-LRD-z9 galaxy. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Yahoo
7 days ago
- Yahoo
James Webb telescope spots earliest black hole in the known universe, looking 'as far back as you can practically go'
When you buy through links on our articles, Future and its syndication partners may earn a commission. Scientists using the James Webb Space Telescope (JWST) have identified the earliest black hole found thus far, dating back to more than 13 billion years ago. The black hole and its home galaxy, together dubbed CAPERS-LRD-z9, existed just 500 million years after the Big Bang. Its properties could help researchers understand what the universe was like in that elusive early era, according to a study published August 6 in the Astrophysical Journal Letters. "When looking for black holes, this is about as far back as you can practically go," study coauthor Anthony Taylor, an astronomer at the University of Texas, Austin, said in a statement. "We're really pushing the boundaries of what current technology can detect." CAPERS-LRD-z9 is a type of galaxy called a "Little Red Dot," so named because they're small (as galaxies go) and appear to emit red light when observed with JWST's powerful infrared sensors. Little Red Dots shine brightly, which might suggest they contain a lot of stars — except they formed in the early universe, when an abundance of stars was unlikely, according to current leading theories of cosmology. "The discovery of Little Red Dots was a major surprise from early JWST data, as they looked nothing like galaxies seen with the Hubble Space Telescope," study coauthor Steven Finkelstein, an astronomer at UT Austin, said in the statement. "Now, we're in the process of figuring out what they're like and how they came to be." To better understand the nature of CAPERS-LRD-z9 and Little Red Dots like it, researchers investigated the galaxy with the JWST. The team found a distinct pattern of wavelengths of light created when fast-moving gas falls into a black hole. Though astronomers have found a few objects farther away than CAPERS-LRD-z9 that might be black holes, this pattern makes CAPERS-LRD-z9 the earliest confirmed black hole to date and suggests that black holes might lie at the center of other Little Red Dots. Related: James Webb telescope captures one of the deepest-ever views of the universe — Space photo of the week The black hole at the center of CAPERS-LRD-z9 is pretty hefty. It's some 38 million times more massive than the sun or about 10 times more massive than Sagittarius A*, the supermassive black hole at the center of the Milky Way — though there's considerable wiggle room in that estimate. The scientists also think that the black hole has as much mass as about 5% of all the stars in its galaxy put together, a ratio far exceeding that of modern galaxies. "This adds to growing evidence that early black holes grew much faster than we thought possible," Finkelstein said. "Or they started out far more massive than our models predict." RELATED STORIES —Scientists detect most massive black hole merger ever — and it birthed a monster 225 times as massive as the sun —Black holes may obey the laws of physics after all, new theory suggests —Behold the first direct image of a supermassive black hole spewing a jet of particles CAPERS-LRD-z9 could also help explain why Little Red Dots are red. A dense cloud of gas surrounding the black hole could shift any emitted light into longer, redder wavelengths, the researchers predicted. Further studies of CAPERS-LRD-z9 could offer even more information about black holes and galaxies in the early universe, the scientists wrote in the study. "This is a good test object for us," Taylor said in the statement. "We haven't been able to study early black hole evolution until recently, and we are excited to see what we can learn from this unique object." Solve the daily Crossword
Yahoo
11-08-2025
- Yahoo
One-size-fits-all pancreatic cancer vaccine showed promise in early trial
In an early trial, a one-size-fits-all vaccine showed promise in preventing hard-to-treat pancreatic cancers from coming back. Pancreatic cancer is of particular concern. The five-year survival rate is about 13%, and up to 80% of pancreatic cancers may come back. 'If you were to ask me what disease most needs something to prevent recurrences, I'd say this one,' said Dr. Zev Wainberg co-director of the University of California, Los Angeles, gastrointestinal oncology program, who co-led the Phase 1 clinical trial. The vaccine targets one of the most common genetic drivers of cancer: KRAS gene mutations. KRAS mutations occur in about one-quarter of all cancers, including as much as 90% of pancreatic cancers and about 40% of colorectal cancers. Their ubiquity makes KRAS mutations a great target for cancer therapies, but the mutations have long been considered impossible to target with drugs. To accomplish this, the vaccine uses short chains of amino acids called peptides that teach immune cells to recognize and attack cells with KRAS mutations. 'The critical step is engaging an immune response,' Wainberg said. Cancer vaccines are a growing field of research, but many of these vaccines are personalized to the patient. This means their tumor must be sequenced for a specialized vaccine to be created. The vaccine in the current study, however, doesn't need to be personalized and would be available off the shelf. Killing lingering cancer cells In the Phase 1 trial, published Monday in Nature Medicine, Wainberg and a team of doctors from across the country recruited 20 people with pancreatic cancer and five with colorectal cancer. (They chose to also include a few colorectal cancer patients because KRAS mutations are also a common driver of colorectal cancers, and people whose colorectal cancer is driven by these mutations are more likely to have a recurrence, Wainberg said.) Everyone in the trial had KRAS mutations and had undergone standard treatment — usually chemotherapy and surgery — to remove the bulk of their tumors. After surgery, blood tests showed that a smattering of cancer cells remained behind, referred to as microscopic residual disease, which is very common with pancreatic cancer. 'We are talking about cancer that is so microscopic that we can't see it on scans,' said Dr. Scott Kopetz, a professor of gastrointestinal medical oncology at the University of Texas MD Anderson Cancer Center in Houston. These cells can travel elsewhere in the body and grow into metastasized tumors, prompting an often fatal cancer recurrence. Chemotherapy can kill some of these cells, but some usually remain in the body. 'Realistically, if we want to kill every last cancer cell and really make people cured, you need to engage the immune system,' said Stephanie Dougan, an associate professor of cancer immunology and virology at the Dana-Farber Cancer Institute in Boston. 'We've just been really bad at getting an immune response in pancreatic cancer.' Post-surgery, everyone in the trial got up to six priming doses of the experimental vaccine, called ELI-002 2P. Thirteen also received booster shots. The whole process took 6 months. About 85% — 21 of the 25 participants — mounted an immune response to the KRAS mutations, and about two-thirds of those patients had an immune response that appeared to be robust enough to stave off lingering cancer cells. What's more, in nearly 70% of people in the trial, the vaccine appeared to trigger an immune response not just to KRAS mutations, but to other tumor cell targets that were not in the vaccine. A few people were 'super-responders' who mounted an abnormally strong immune response to the cells. 'Those people had the best outcomes,' Wainberg said. His team is currently running a randomized Phase 2 trial to test the durability of the vaccine and compare whether the vaccine is more effective than the standard of care, which would usually be monitoring the patient for a recurrence. In the Phase 1 trial, people with pancreatic cancer survived for an average of 29 months and lived recurrence-free for more than 15 months post-vaccination. 'That far exceeds the rates with resectable cancers,' said Wainberg, referring to cancers that can be removed with surgery. A growing field Cancer vaccines have been incredibly difficult to make, in part because cancer cells have a lot of the same proteins as healthy cells, making safe targets difficult to come by. Only recently has medical technology made the strides researchers needed to hone the treatment. Refined mRNA technology and gene sequencing becoming faster and cheaper has put cancer vaccines back into clinical trials, Dougan said. Personalized mRNA cancer vaccines are showing promise in both pancreatic and colorectal cancers, but a one-size-fits-all cancer vaccine would make treatment faster and cheaper. Past trials using peptide vaccines have failed to prevent cancer recurrences. But the peptides in the new vaccine, called lipophilic peptides, have something past treatments did not — a tail. 'That tail sticks in the lymph nodes where immune cells get activated,' Dougan said. 'You need something to get the immune system going, and just injecting killed cancer cells or peptides doesn't work that well.' More advanced clinical trials will have to confirm the results of the Phase 1 trial, but promising results have been seen in other cancer vaccine trials as well and could pave the way for major breakthroughs in preventing cancer recurrences. Memorial Sloan Kettering is also working on an off-the-shelf vaccine that targets a gene mutation found in 95% of people with acute myeloid leukemia. The data from the KRAS-targeting vaccine trial published Monday showed it is likely possible to target these mutations with nonpersonalized vaccines, something researchers long thought was impossible. 'The fact that the long-term survival really correlated with T-cell response suggests that the vaccine caused this,' Dougan said, referring to the specific immune cells activated by the vaccine. 'The idea that you can target KRAS is really exciting.' This article was originally published on Solve the daily Crossword
